{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:09Z","timestamp":1791928629393,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ygyno.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T10:41:33Z","timestamp":1739011293000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study"],"prefix":"10.1016","volume":"194","author":[{"given":"Carmine","family":"Valenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mongillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalissa","family":"Katrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Farfalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Malengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Derio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Lapresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Omodeo Sal\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.01.014_bb0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0010","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-positive, platinum-resistant ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0015","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian Cancer consensus conference of the gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0035","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0040","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1995.13.7.1584","article-title":"Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer","volume":"13","author":"Kavanagh","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ijgc-00009577-200503000-00004","article-title":"Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance","volume":"15","author":"See","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0050","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0055","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1002\/cncr.30830","article-title":"Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?","volume":"123","author":"Tomao","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0060","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study","volume":"35","author":"Pignata","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0065","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41416-022-02108-7","volume":"128","author":"Colombo","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112944","article-title":"Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments","volume":"190","author":"Valenza","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.01.014_bb0080","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0085","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.2023.41.16_suppl.5550","article-title":"Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1\/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (Ola) maintenance","volume":"41","author":"Harter","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.01.014_bb0095","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/j.annonc.2022.07.646","article-title":"518O overall survival results from ARIEL4: a phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:16:48Z","timestamp":1744319808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"alternative-id":["S0090825825000265"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.01.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}